Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.06% Nasdaq Down0.01%

Avanir Pharmaceuticals, Inc. (AVNR)

-NasdaqGS

3.41 Up 0.01(0.29%) May 24, 4:00PM EDT|After Hours : 3.40 Down 0.01 (0.29%) May 24, 5:00PM EDT

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 30, 2013Dec 30, 2012Sep 29, 2012Jun 29, 2012
Total Revenue 17,434   16,520   13,532   10,538  
Cost of Revenue1,003  848  713  564  
Gross Profit 16,432   15,673   12,819   9,974  
Operating Expenses
Research Development8,874  6,648  6,095  6,831  
Selling General and Administrative23,040  20,061  17,400  17,855  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (15,483) (11,036) (10,676) (14,712)
Income from Continuing Operations
Total Other Income/Expenses Net15  19  13  8  
Earnings Before Interest And Taxes(15,467)(11,017)(10,663)(14,704)
Interest Expense1,059  1,059  1,059  326  
Income Before Tax(16,527)(12,076)(11,722)(15,030)
Income Tax Expense -   -  3   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(16,527)(12,076)(11,725)(15,030)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (16,527) (12,076) (11,725) (15,030)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (16,527) (12,076) (11,725) (15,030)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.